Aurigene Oncology
- Company typePrivate
- Founded2001
- HeadquartersBangalore, India
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
Aurigene Oncology firmographics
Firmographics- Name
- Aurigene Oncology
- Legal name
- Aurigene Discovery Technologies Limited
- Website
- https://aurigene.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
Aurigene Oncology industry classification
Industry- Product category
- Oncology Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Aurigene Oncology is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
Aurigene Oncology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Licensing and Milestone Payments: Aurigene out-licenses proprietary programs to global pharma and biotech companies. Revenue is generated through upfront payments, clinical development and regulatory milestones, commercial milestones, and royalties on net sales. Example: Olema deal included $8M upfront, up to $60M in clinical/regulatory milestones, up to $370M in commercial milestones, plus mid-single to low double digit royalties.
- Co-development and Collaborative Research: Multi-year multi-program partnerships where Aurigene leads discovery and preclinical development while partners fund and lead clinical development, manufacturing, regulatory, and commercialization. Example: EQRx multi-program partnership for oncology and immune-inflammatory diseases with shared funding and financials from commercialization.
- Self-sustaining Operations (Non-dilutive Revenue): Capital-efficient operating model with India-based infrastructure enabling faster and cost-effective R&D. Self-sustainable operations provide non-dilutive, recurring revenue. The company has achieved breakeven in past (per milestones page).
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Aurigene Oncology product offering
Product offeringCore offering
Aurigene Oncology is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule and cell therapy oncology drug candidates using proprietary platforms including targeted protein degradation (A-PROX), small molecule immuno-oncology, kinase inhibition, peptides, antibody engineering, and AI/ML for drug discovery. The company monetizes its pipeline primarily by licensing drug candidates to global pharmaceutical and biotechnology partners through upfront payments, development/commercial milestones, and royalties, while also conducting proprietary clinical development in India and partnering with government bodies like ICMR.
Product overview
Aurigene Oncology is a clinical-stage biopharmaceutical company with a diversified portfolio of novel cancer therapeutics spanning multiple modalities. The core portfolio includes small molecule programs (Cenopodlin, AUR103-AUR112) targeting immune checkpoints (VISTA, CD47, TIGIT), epigenetic targets (CBP/p300, PRMT5, RORgt), kinases (DDR1/SIK2, IRAK4), and enzymes (DHODH, MALT1), as well as cell therapy (Ribrecabtagene autoleucel CAR-T). These are supported by technology platforms including A-PROX for targeted protein degradation, an AI/ML platform for drug discovery acceleration, directed neo-substrate degrader platform, small molecule IO platform, kinase inhibitor platform, peptides platform, and antibody engineering platform. The company operates from Bangalore, India with GMP manufacturing capabilities including a CAR-T facility.
Differentiator
Problem solved
Functional benefit
Products and services
- Cenopodlin (AUR102 / CA-170)
- AUR103
- AUR104
- AUR105
- AUR106
- AUR107
- AUR108
- AUR109
- AUR101
- AUR110
- AUR112
- Ribrecabtagene autoleucel (DRL-1801)
Quantifiable outcome
- 63.6% overall response rate in efficacy-evaluable patients for AUR112 in relapsed/refractory lymphoid malignancies (Phase 1)
- +4 more outcomes
Companies that use Aurigene Oncology
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles3 records
Aurigene Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature7 records
Aurigene Oncology partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered minor and core.
- EdityminorAurigene to provide cell therapy discovery services to Edity to support clinical development. Aurigene's CAR-T GMP manufacturing facility and cell therapy expertise are leveraged for Edity's programs.
- Indian Council of Medical Research (ICMR)coreMoA under ICMR's Network of Phase 1 Clinical Trials. Collaborative research over a small molecule for multiple myeloma. Marks pivotal step towards establishing India's self-sufficiency in clinical development. ICMR Network comprises KEMH & GSMC Mumbai, ACTREC Navi Mumbai, SRM MCH&RC Kattankulathur, and PGIMER Chandigarh, supported by a Central Coordinating Unit at ICMR HQ New Delhi.
- EQRxcoreMulti-program drug discovery, development, and commercialization partnership covering oncology and immune-inflammatory diseases. Aurigene leads discovery and preclinical development; EQRx assumes clinical development, manufacturing, regulatory, and commercialization. Parties share funding and commercialization financials. Validates Aurigene's discovery platform and moves the company into building a global oncology franchise.
- Olema OncologycoreExclusive global license agreement to research, develop, and commercialize novel small molecule inhibitors of an undisclosed oncology target. $8M upfront, up to $60M in clinical/regulatory milestones, up to $370M in commercial milestones, plus mid-single to low double digit royalties on net sales. Olema leads clinical development and commercialization; Aurigene contributed pre-existing program.
- CuriscoreMulti-program licensing agreement. IRAK4 inhibitor CA-4948 (emavusertib) licensed to Curis for global development in hematologic malignancies. Aurigene retains certain rights.
- NovartiscoreMulti-year, multi-target strategic partnerships for drug discovery. A candidate from the Novartis collaboration entered Phase 1.
- JanssencoreMulti-year, multi-target strategic partnerships for drug discovery.
- ExelixiscoreMulti-program licensing deal for developing drugs for oncology.
- AgioscoreLicensing agreement with Agios for development of drug candidates.
- AstellascoreLicensed programs including PPARδ modulators ASP0367 and ASP1128. Astellas acquired Mitobridge (formerly partnered with Aurigene).
- EisaicoreFirst biotech partnership with H3 Biomedicine (subsidiary of Eisai). ESR1 ligand H3B-6545 in clinical development.
- Asana BiosciencesminorLicensed SYK/JAK inhibitor ASN002 and BRAK/PI3K inhibitor ASN003 to Asana Biosciences.
- Orion PharmaminorOption licensing deal with Orion Pharma for development of drug candidates.
- Mitobridge (Astellas)minorPartnership with US biotech Mitobridge (currently an Astellas company) for development of PPARδ modulator programs.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Aurigene Oncology competitors and assessment
Company assessmentDirect peers
- Curis: Small US clinical-stage oncology company that licensed Aurigene's IRAK4 inhibitor (emavusertib/CA-4948). Operates a similar licensing-partnered model focused on hematologic malignancies, making it a directly comparable business model.
- Arvinas: US clinical-stage biotech pioneering targeted protein degradation (PROTAC platform) for oncology indications. Directly comparable to Aurigene's A-PROX platform in modality, target classes, and partnership-driven economics.
- Kymera Therapeutics: Clinical-stage degrader-focused biotech developing targeted protein degradation therapies in oncology and immunology. Overlapping technology platform (molecular glues/PROTACs) and similar early-clinical scaling dynamics make it a key direct peer.
- Nurix Therapeutics: Clinical-stage biotech developing small-molecule degrader therapies for oncology using ligase-directed chemistry. Comparable target-class breadth, partnership approach with large pharma, and degrader-platform focus.
- Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin regulation, including SMARCA2/4 and other SWI/SNF members. Highly comparable target overlap (SMARCA2 degraders) and oncology-discovery operating model.
- Olema Oncology: US clinical-stage oncology biotech with a licensing deal covering an undisclosed Aurigene-discovered target. Similar clinical-stage, partner-licensed business model and oncology focus.
Broad incumbents
- Exelixis: Established US oncology company with a multi-asset pipeline including kinase inhibitors and partnered programs with Aurigene. Larger and commercially active, but overlapping modality and partner-style deal flow.
- Agios Pharmaceuticals: Established oncology and rare-disease biotech that has licensed candidate programs from Aurigene. Comparable focus on small molecule oncology and partnership-driven development, but with deeper commercial footprint.
Regional players
- Jubilant Biosys: India-based integrated drug discovery CRO operating from Bangalore. Geographic and operational overlap with Aurigene's India-based discovery platform, though focused on services rather than proprietary clinical assets.
Others
- Syngene International: India-listed contract research organization offering discovery, development, and manufacturing services to global pharma. Plays an adjacent India-discovery ecosystem role alongside Aurigene's in-house capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Aurigene Oncology social profiles
Digital presenceAurigene Oncology compliance and trust
Trust signalCompliance1 record
Aurigene Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aurigene Oncology leadership team
Management profileNumber of profiles
Profiles16 records
Aurigene Oncology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aurigene Oncology M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aurigene Oncology
What does Aurigene Oncology do?
Aurigene Oncology is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule and cell therapy oncology drug candidates using proprietary platforms including targeted protein degradation (A-PROX), small molecule immuno-oncology, kinase inhibition, peptides, antibody engineering, and AI/ML for drug discovery. The company monetizes its pipeline primarily by licensing drug candidates to global pharmaceutical and biotechnology partners through upfront payments, development/commercial milestones, and royalties, while also conducting proprietary clinical development in India and partnering with government bodies like ICMR.
Is Aurigene Oncology a public or private company?
Aurigene Oncology is a private company. It is classified as corporate owned and is currently operating.
When was Aurigene Oncology founded?
Aurigene Oncology was founded in 2001. It employs 501 to 1,000 people.
Where is Aurigene Oncology based?
Aurigene Oncology is headquartered in Bangalore, India, in the Asia region.
How does Aurigene Oncology make money?
Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are co-development and Collaborative Research and self-sustaining Operations (Non-dilutive Revenue).
Who are Aurigene Oncology's main competitors?
Direct peers on record are Curis, Arvinas, Kymera Therapeutics, Nurix Therapeutics, Foghorn Therapeutics and Olema Oncology. Broad incumbents are Exelixis and Agios Pharmaceuticals. Jubilant Biosys is listed as a regional player. Syngene International is listed as an others.
Does Aurigene Oncology have an API?
No public API is recorded for Aurigene Oncology.
What industry is Aurigene Oncology in?
Aurigene Oncology's product category is Oncology Drug Discovery. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.